Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncolo... (statements involve risk and uncertaintie...)

Breaking Medicine News(10 mins):Health News:Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients 2 Health News:Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges' 2 Health News:Kaiser Permanente CIO Philip Fasano Named One of Computerworld's Top 100 IT Leaders for 2010 2 Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 2 Health News:Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 3 Health News:Second-line CML drugs evoke faster response than front-line therapy 2

[1] Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients [0] Hospice Foundation of America Presents Webinar on 'Bereavement Camps for Kids: Benefits and Challenges'[0] Kaiser Permanente CIO Philip Fasano Named One of Computerworld's Top 100 IT Leaders for 2010 [0] Lung Cancer Alliance-Georgia Hails Senate Leadership on Lung Cancer Mortality Reduction Act of 2009 [0] Second-line CML drugs evoke faster response than front-line therapy

ADA Urges President Bush Not to Veto Critical Appropriations Bill AUA releases new guidelines on non-muscle invasive bladder cancer Warning for women who binge drink Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 New Study: Health Insurance Mandates on Employers Hurt Low-Income Employees Physics provides new insights on cataract formation

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2 Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 2 Van Andel Institute Cuts Ribbon on $178 Million Expansion 3 Van Andel Institute Cuts Ribbon on $178 Million Expansion 4 Call to the Youth of America 3A Palms for Life Fund Launches Film Competition to Document Hunger in the United States 53180 1 Call to the Youth of America 3A Palms for Life Fund Launches Film Competition to Document Hunger in the United States 53180 2 All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 53176 1 All Nursing Schools Sheds Light on Online Nursing Degree Opportunities in a Rough Economy 53176 2 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 1 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 2 Higher drug doses needed to defeat tuberculosis UT Southwestern researchers report 53172 3

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program [0] Van Andel Institute Cuts Ribbon on $178 Million Expansion

Other Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2 Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3 Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 2 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 3 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting 4

Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting

Medicine Products:

Allsport Ankle Ortho II QualCare™ Compression Ankle Support VenaFlow® System SCD EXPRESS Compression System

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncolo...(statements involve risk and uncertaintie...),Health